I think there are few small buckets of risk. The first is the risk of anaphylactic shock—that can be a problem for a small number of people, and it’s not a risk unique to this study. Another small bucket of risk, and it’s not clear if it’s relevant to covid-19, is called antibody-dependent enhancement [when a vaccine makes a disease worse]. That is part of what they are evaluating, I suppose. And the third bucket of risk is the unanticipated. That exists for any vaccine, especially one based on new technology.